Plain-English translation of NCT00512239 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This research study is looking for early warning signs that can predict which patients with newly diagnosed inflammatory joint disease will develop severe arthritis. Researchers are examining blood tests and other markers to understand which patients need more aggressive treatment early on, and to learn whether certain antibodies (anti-Sa and anti-CCP) can help identify patients at higher risk of developing serious joint damage.
Many effective treatments are now available for inflammatory arthritis, but they work best when started early. However, doctors currently cannot reliably predict which patients will develop severe disease and which patients will have milder disease. This study aims to fill that gap by identifying blood and clinical markers that can predict disease severity, so treatment decisions can be personalized from the start.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital rheumatology clinic for initial evaluation and blood work. Over the next 5 years, you would have follow-up appointments at 18 months, 30 months, 42 months, and 60 months after your initial diagnosis, where doctors would assess your joint health, take blood samples, and perform imaging tests (like X-rays) to monitor disease progression. The research team would track how your disease develops over time and use this information to improve how doctors predict outcomes in newly diagnosed patients.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Canada